Skip to main content
Erschienen in: Tumor Biology 12/2014

01.12.2014 | Research Article

miR149 rs71428439 polymorphism and risk of clear cell renal cell carcinoma: a case–control study

verfasst von: Zhigang Wang, Meng Wei, Yi Ren, Hua Liu, Meng Wang, Kehui Shi, Hongli Jiang

Erschienen in: Tumor Biology | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

Clear cell renal cell carcinoma (CCRCC) is the most common subtype of renal cell cancer and accounts for 70 % of renal cell cancer. CCRCC remains an enigmatic tumor type, as the molecular genetic mechanisms are still unclear. MicroRNA (miR) 149 functions as a tumor suppressor and plays an important role in the carcinogenesis of renal cells. In this study, we enrolled 1,000 CCRCC patients and 1,000 cancer-free controls to evaluate the association of miR149 rs71428439 with the risk of CCRCC by a case–control study to determine the effects on CCRCC risk. miR149 rs71428439 was significantly associated with increased CCRCC risk (odds ratio (OR) for trend = 1.53, P for trend = 4.04 × 10−11), with ORs (95 % confidence intervals (CIs)) of 1.42 (1.17–1.72) associated with AG genotype and 2.27 (1.76–2.94) associated with GG genotype, compared with subjects with AA genotype. The expression levels of miR149 in cancer tissues were significantly lower than those in adjacent normal tissues (P = 0.005), and per G allele has significantly lower miR149 levels in both tumor tissues and adjacent normal tissues. Our data suggest that the GG genotypes of miR149 rs71428439 predispose their carriers to CCRCC, and miR149 rs71428439 may be a new biomarker for predicting the risk of CCRCC.
Literatur
1.
Zurück zum Zitat Kidney cancer: CXCR4—a prognostic factor for renal cell carcinoma? Nature reviews urology 2014;11:247. Kidney cancer: CXCR4—a prognostic factor for renal cell carcinoma? Nature reviews urology 2014;11:247.
2.
Zurück zum Zitat Loron MC, Grange S, Guerrot D, Di Fiore F, Freguin C, Hanoy M, Le Roy F, Poussard G, Etienne I, Legallicier B, Pfister C, Godin M, Bertrand D: Pneumocystis jirovecii pneumonia in everolimus-treated renal cell carcinoma. J Clin Oncol 2014 Loron MC, Grange S, Guerrot D, Di Fiore F, Freguin C, Hanoy M, Le Roy F, Poussard G, Etienne I, Legallicier B, Pfister C, Godin M, Bertrand D: Pneumocystis jirovecii pneumonia in everolimus-treated renal cell carcinoma. J Clin Oncol 2014
3.
Zurück zum Zitat De Meerleer G, Khoo V, Escudier B, Joniau S, Bossi A, Ost P, et al. Radiotherapy for renal cell carcinoma. Lancet Oncol. 2014;15:e170–7.CrossRef De Meerleer G, Khoo V, Escudier B, Joniau S, Bossi A, Ost P, et al. Radiotherapy for renal cell carcinoma. Lancet Oncol. 2014;15:e170–7.CrossRef
4.
Zurück zum Zitat Lornoy W, Becaus S, de Vleeschouwer M, Morelle V, Fonteyne E, Thienpoint L, et al. Renal cell carcinoma, a new complication of analgesic nephropathy. Lancet. 1986;1:1271–2.CrossRef Lornoy W, Becaus S, de Vleeschouwer M, Morelle V, Fonteyne E, Thienpoint L, et al. Renal cell carcinoma, a new complication of analgesic nephropathy. Lancet. 1986;1:1271–2.CrossRef
5.
Zurück zum Zitat Renal cell carcinoma. Lancet 1976;2:887–888. Renal cell carcinoma. Lancet 1976;2:887–888.
6.
Zurück zum Zitat Brugarolas J: Molecular genetics of clear-cell renal cell carcinoma. J Clin Oncol 2014 Brugarolas J: Molecular genetics of clear-cell renal cell carcinoma. J Clin Oncol 2014
7.
Zurück zum Zitat Vergho D, Kneitz S, Rosenwald A, Scherer C, Spahn M, Burger M, et al. Combination of expression levels of miR-21 and miR-126 is associated with cancer-specific survival in clear-cell renal cell carcinoma. BMC Cancer. 2014;14:25.CrossRef Vergho D, Kneitz S, Rosenwald A, Scherer C, Spahn M, Burger M, et al. Combination of expression levels of miR-21 and miR-126 is associated with cancer-specific survival in clear-cell renal cell carcinoma. BMC Cancer. 2014;14:25.CrossRef
8.
Zurück zum Zitat Liang J, Zhang Y, Jiang G, Liu Z, Xiang W, Chen X, et al. MiR-138 induces renal carcinoma cell senescence by targeting EZH2 and is downregulated in human clear cell renal cell carcinoma. Oncol Res. 2014;21:83–91.CrossRef Liang J, Zhang Y, Jiang G, Liu Z, Xiang W, Chen X, et al. MiR-138 induces renal carcinoma cell senescence by targeting EZH2 and is downregulated in human clear cell renal cell carcinoma. Oncol Res. 2014;21:83–91.CrossRef
9.
Zurück zum Zitat Iwamoto H, Kanda Y, Sejima T, Osaki M, Okada F, Takenaka A. Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma. Int J Oncol. 2014;44:53–8.CrossRef Iwamoto H, Kanda Y, Sejima T, Osaki M, Okada F, Takenaka A. Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma. Int J Oncol. 2014;44:53–8.CrossRef
10.
Zurück zum Zitat Huang QB, Ma X, Zhang X, Liu SW, Ai Q, Shi TP, et al. Down-regulated miR-30a in clear cell renal cell carcinoma correlated with tumor hematogenous metastasis by targeting angiogenesis-specific DLL4. PLoS One. 2013;8:e67294.CrossRef Huang QB, Ma X, Zhang X, Liu SW, Ai Q, Shi TP, et al. Down-regulated miR-30a in clear cell renal cell carcinoma correlated with tumor hematogenous metastasis by targeting angiogenesis-specific DLL4. PLoS One. 2013;8:e67294.CrossRef
11.
Zurück zum Zitat Gebauer K, Peters I, Dubrowinskaja N, Hennenlotter J, Abbas M, Scherer R, et al. Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma. Br J Cancer. 2013;108:131–8.CrossRef Gebauer K, Peters I, Dubrowinskaja N, Hennenlotter J, Abbas M, Scherer R, et al. Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma. Br J Cancer. 2013;108:131–8.CrossRef
12.
Zurück zum Zitat Zhao A, Li G, Peoc’h M, Genin C, Gigante M. Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol. 2013;94:115–20.CrossRef Zhao A, Li G, Peoc’h M, Genin C, Gigante M. Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol. 2013;94:115–20.CrossRef
13.
Zurück zum Zitat Mikhaylova O, Stratton Y, Hall D, Kellner E, Ehmer B, Drew AF, et al. VHL-regulated MiR-204 suppresses tumor growth through inhibition of LC3B-mediated autophagy in renal clear cell carcinoma. Cancer Cell. 2012;21:532–46.CrossRef Mikhaylova O, Stratton Y, Hall D, Kellner E, Ehmer B, Drew AF, et al. VHL-regulated MiR-204 suppresses tumor growth through inhibition of LC3B-mediated autophagy in renal clear cell carcinoma. Cancer Cell. 2012;21:532–46.CrossRef
14.
Zurück zum Zitat Valera VA, Walter BA, Linehan WM, Merino MJ. Regulatory effects of microRNA-92 (miR-92) on VHL gene expression and the hypoxic activation of miR-210 in clear cell renal cell carcinoma. J Cancer Educ. 2011;2:515–26.CrossRef Valera VA, Walter BA, Linehan WM, Merino MJ. Regulatory effects of microRNA-92 (miR-92) on VHL gene expression and the hypoxic activation of miR-210 in clear cell renal cell carcinoma. J Cancer Educ. 2011;2:515–26.CrossRef
15.
Zurück zum Zitat Song T, Zhang X, Wang C, Wu Y, Cai W, Gao J, et al. miR-138 suppresses expression of hypoxia-inducible factor 1alpha (HIF-1alpha) in clear cell renal cell carcinoma 786-O cells. Asian Pac J Cancer Prev. 2011;12:1307–11.PubMed Song T, Zhang X, Wang C, Wu Y, Cai W, Gao J, et al. miR-138 suppresses expression of hypoxia-inducible factor 1alpha (HIF-1alpha) in clear cell renal cell carcinoma 786-O cells. Asian Pac J Cancer Prev. 2011;12:1307–11.PubMed
16.
Zurück zum Zitat Hildebrandt MA, Gu J, Lin J, Ye Y, Tan W, Tamboli P, et al. Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene. 2010;29:5724–8.CrossRef Hildebrandt MA, Gu J, Lin J, Ye Y, Tan W, Tamboli P, et al. Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene. 2010;29:5724–8.CrossRef
17.
Zurück zum Zitat Omrani M, Hashemi M, Eskandari-Nasab E, Hasani SS, Mashhadi MA, Arbabi F, et al. hsa-miR-499 rs3746444 gene polymorphism is associated with susceptibility to breast cancer in an Iranian population. Biomark Med. 2014;8:259–67.CrossRef Omrani M, Hashemi M, Eskandari-Nasab E, Hasani SS, Mashhadi MA, Arbabi F, et al. hsa-miR-499 rs3746444 gene polymorphism is associated with susceptibility to breast cancer in an Iranian population. Biomark Med. 2014;8:259–67.CrossRef
18.
Zurück zum Zitat Chae YS, Kim JG, Lee SJ, Kang BW, Lee YJ, Park JY, et al. A miR-146a polymorphism (rs2910164) predicts risk of and survival from colorectal cancer. Anticancer Res. 2013;33:3233–9.PubMed Chae YS, Kim JG, Lee SJ, Kang BW, Lee YJ, Park JY, et al. A miR-146a polymorphism (rs2910164) predicts risk of and survival from colorectal cancer. Anticancer Res. 2013;33:3233–9.PubMed
19.
Zurück zum Zitat Du W, Ma X, Kong W, Liu T, Wei B, Yu J, et al. Association between rs11614913 polymorphism in miR-196a2 and colorectal cancer risk: a meta-analysis. Cancer Biomark. 2013;13:457–64.CrossRef Du W, Ma X, Kong W, Liu T, Wei B, Yu J, et al. Association between rs11614913 polymorphism in miR-196a2 and colorectal cancer risk: a meta-analysis. Cancer Biomark. 2013;13:457–64.CrossRef
20.
Zurück zum Zitat Lin Y, Nie Y, Zhao J, Chen X, Ye M, Li Y, et al. Genetic polymorphism at miR-181a binding site contributes to gastric cancer susceptibility. Carcinogenesis. 2012;33:2377–83.CrossRef Lin Y, Nie Y, Zhao J, Chen X, Ye M, Li Y, et al. Genetic polymorphism at miR-181a binding site contributes to gastric cancer susceptibility. Carcinogenesis. 2012;33:2377–83.CrossRef
21.
Zurück zum Zitat Wang F, Ma YL, Zhang P, Shen TY, Shi CZ, Yang YZ, et al. SP1 mediates the link between methylation of the tumour suppressor miR-149 and outcome in colorectal cancer. J Pathol. 2013;229:12–24.CrossRef Wang F, Ma YL, Zhang P, Shen TY, Shi CZ, Yang YZ, et al. SP1 mediates the link between methylation of the tumour suppressor miR-149 and outcome in colorectal cancer. J Pathol. 2013;229:12–24.CrossRef
22.
Zurück zum Zitat Bischoff A, Huck B, Keller B, Strotbek M, Schmid S, Boerries M, Busch H, Muller D, Olayioye MA: miR-149 functions as a tumor suppressor by controlling breast epithelial cell migration and invasion. Cancer Res 2014 Bischoff A, Huck B, Keller B, Strotbek M, Schmid S, Boerries M, Busch H, Muller D, Olayioye MA: miR-149 functions as a tumor suppressor by controlling breast epithelial cell migration and invasion. Cancer Res 2014
23.
Zurück zum Zitat Ke Y, Zhao W, Xiong J, Cao R. miR-149 inhibits non-small-cell lung cancer cells EMT by targeting FOXM1. Biochem res int. 2013;2013:506731.CrossRef Ke Y, Zhao W, Xiong J, Cao R. miR-149 inhibits non-small-cell lung cancer cells EMT by targeting FOXM1. Biochem res int. 2013;2013:506731.CrossRef
24.
Zurück zum Zitat Lin RJ, Lin YC, Yu AL. miR-149* induces apoptosis by inhibiting Akt1 and E2F1 in human cancer cells. Mol Carcinog. 2010;49:719–27.CrossRef Lin RJ, Lin YC, Yu AL. miR-149* induces apoptosis by inhibiting Akt1 and E2F1 in human cancer cells. Mol Carcinog. 2010;49:719–27.CrossRef
25.
Zurück zum Zitat Ding SL, Wang JX, Jiao JQ, Tu X, Wang Q, Liu F, et al. A pre-microRNA-149 (miR-149) genetic variation affects miR-149 maturation and its ability to regulate the Puma protein in apoptosis. J Biol Chem. 2013;288:26865–77.CrossRef Ding SL, Wang JX, Jiao JQ, Tu X, Wang Q, Liu F, et al. A pre-microRNA-149 (miR-149) genetic variation affects miR-149 maturation and its ability to regulate the Puma protein in apoptosis. J Biol Chem. 2013;288:26865–77.CrossRef
26.
Zurück zum Zitat Mori M, Triboulet R, Mohseni M, Schlegelmilch K, Shrestha K, Camargo FD, et al. Hippo signaling regulates microprocessor and links cell-density-dependent miRNA biogenesis to cancer. Cell. 2014;156:893–906.CrossRef Mori M, Triboulet R, Mohseni M, Schlegelmilch K, Shrestha K, Camargo FD, et al. Hippo signaling regulates microprocessor and links cell-density-dependent miRNA biogenesis to cancer. Cell. 2014;156:893–906.CrossRef
27.
Zurück zum Zitat Sozzi G, Boeri M, Rossi M, Verri C, Suatoni P, Bravi F, et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative mild trial study. J Clin Oncol. 2014;32:768–73.CrossRef Sozzi G, Boeri M, Rossi M, Verri C, Suatoni P, Bravi F, et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative mild trial study. J Clin Oncol. 2014;32:768–73.CrossRef
28.
Zurück zum Zitat Heneghan HM, Miller N, Kerin MJ: Circulating miRNA signatures: promising prognostic tools for cancer. J Clin Oncol 2010;28:e573-574; author reply e575-576. Heneghan HM, Miller N, Kerin MJ: Circulating miRNA signatures: promising prognostic tools for cancer. J Clin Oncol 2010;28:e573-574; author reply e575-576.
29.
Zurück zum Zitat Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell. 2009;138:592–603.CrossRef Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell. 2009;138:592–603.CrossRef
30.
Zurück zum Zitat Ruvkun G. Clarifications on miRNA and cancer. Science. 2006;311:36–7.CrossRef Ruvkun G. Clarifications on miRNA and cancer. Science. 2006;311:36–7.CrossRef
31.
Zurück zum Zitat Mezzanzanica D, Canevari S, Cecco LD, Bagnoli M. miRNA control of apoptotic programs: focus on ovarian cancer. Expert Rev Mol Diagn. 2011;11:277–86.CrossRef Mezzanzanica D, Canevari S, Cecco LD, Bagnoli M. miRNA control of apoptotic programs: focus on ovarian cancer. Expert Rev Mol Diagn. 2011;11:277–86.CrossRef
32.
Zurück zum Zitat Wang Y, Zhang X, Li H, Yu J, Ren X. The role of miRNA-29 family in cancer. Eur J Cell Biol. 2013;92:123–8.CrossRef Wang Y, Zhang X, Li H, Yu J, Ren X. The role of miRNA-29 family in cancer. Eur J Cell Biol. 2013;92:123–8.CrossRef
33.
Zurück zum Zitat Zadran S, Remacle F, Levine RD. miRNA and mRNA cancer signatures determined by analysis of expression levels in large cohorts of patients. Proc Natl Acad Sci U S A. 2013;110:19160–5.CrossRef Zadran S, Remacle F, Levine RD. miRNA and mRNA cancer signatures determined by analysis of expression levels in large cohorts of patients. Proc Natl Acad Sci U S A. 2013;110:19160–5.CrossRef
Metadaten
Titel
miR149 rs71428439 polymorphism and risk of clear cell renal cell carcinoma: a case–control study
verfasst von
Zhigang Wang
Meng Wei
Yi Ren
Hua Liu
Meng Wang
Kehui Shi
Hongli Jiang
Publikationsdatum
01.12.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 12/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2517-5

Weitere Artikel der Ausgabe 12/2014

Tumor Biology 12/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.